Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | August 29, 2012

When PET Fails

We want absolutes; things we can depend on; certainties in an unfortunately uncertain world. It’s the kind of faith we put into positron emission tomography/computed tomography (PET/CT), even when it’s not warranted.

More than a year ago, the German Institute for Quality and Efficiency in Health Care released a study concluding that there was a dearth of support for the use of PET/CT as a reliable aid in diagnosing or monitoring for the return of melanoma. A systematic search found no published studies to indicate the relevance of PET or PET/CT in either primary staging or in the detection of recurrences of malignant melanoma. Nor was any research uncovered indicating the prognostic accuracy of this technique.

In the absence of documented failures or successes, PET/CT continues to be used by some physicians to stage melanoma or monitor patients for its recurrence. Its results are used, consequently, to ease patient worries, sometimes incorrectly.

So it was that a long-time friend of mine, who had been battling melanoma for the past six years, received a PET/CT, embraced its negative findings, then weeks later encountered symptoms that led him to undergo a brain CT, which revealed a large tumor in his parietal and temporal lobes.

In mainstream medical practice, FDG-PET is considered essential for staging and monitoring patients battling cancers such as lymphoma and that of the lung, according to Michael Vannier, M.D., professor of radiology at the University of Chicago. But PET has specific and significant limitations. These are often related to the type of disease, the isotopic agent and the size of the lesion, Vannier explained.

“We sometimes find that PET has been used inappropriately for certain tumor types. Renal cell cancer and prostate cancer are notoriously difficult to image with FDG-PET,” he told me.

Add melanoma to that list.

When PET/CT is used to do what it cannot do effectively, it may be an expression of an old maxim –  that when all you have is a hammer, everything looks like a nail.

In this age of dwindling resources, we need to be a little pickier about what we hammer. The financial costs of doing so indiscriminately are high. Yet they pale when compared to the emotional price paid by patients whose belief in a bright future is unwarranted.

Related Content

First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

Sponsored Content | Case Study | Radiation Dose Management | August 13, 2019
Radiation dose management is central to child patient safety. Medical imaging plays an increasing role in the accurate...